Neuropathy in chronic kidney disease

I. Wittmann, A. Stirban, S. Tesfaye, I. Gurieva, L. Czupryniak, B. N. Mankovsky, V. Spallone, I. A. Veresiu, O. Schnell, D. Ziegler, G. A. Molnár, M. Erbach, P. Kempler

Research output: Contribution to journalArticle

Abstract

Chronic kidney disease (CKD) has seen increasing prevalence, with current levels at around ten percent in adults aged twenty and over in industrialized western countries. CKD frequently affects both the central nervous system (CNS) and peripheral nervous system (PNS); uraemia, advanced glycation end-product (AGE) accumulation and oxidative stress, hyperkalemia, insulin resistance, adipocytokines, and erythropoietin deficiency and resistance have been identified as potential triggering factors. Typical neurological sequelae include uraemic encephalopathy, dialysis disequilibrium syndrome, and uraemic polyneuropathy. Impaired cerebral cognitive function has been demonstrated even in clinically asymptomatic stages in uraemic patients. In general, initiation of renal replacement treatment is indicated as the most promising therapeutic approach, possibly with symptomatic treatment of neuropathic pain with first-line drugs such as gabapentin, pregabalin, tricyclic antidepressants, and duloxetine. Additional treatment with benfotiamine may be considered as a pathogenesis-oriented measure in addressing the important role of inflammation and oxidative stress in the further renal function deterioration and nervous damage.

Original languageEnglish
Pages (from-to)251-255
Number of pages5
JournalDiabetes, Stoffwechsel und Herz
Volume24
Issue number4
Publication statusPublished - Aug 1 2015

Fingerprint

Chronic Renal Insufficiency
Oxidative Stress
Kidney
Hyperkalemia
Advanced Glycosylation End Products
Adipokines
Polyneuropathies
Tricyclic Antidepressive Agents
Uremia
Peripheral Nervous System
Brain Diseases
Neuralgia
Therapeutics
Erythropoietin
Developed Countries
Cognition
Insulin Resistance
Dialysis
Central Nervous System
Inflammation

Keywords

  • Chronic kidney disease
  • Diabetes
  • Neuropathy

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Wittmann, I., Stirban, A., Tesfaye, S., Gurieva, I., Czupryniak, L., Mankovsky, B. N., ... Kempler, P. (2015). Neuropathy in chronic kidney disease. Diabetes, Stoffwechsel und Herz, 24(4), 251-255.

Neuropathy in chronic kidney disease. / Wittmann, I.; Stirban, A.; Tesfaye, S.; Gurieva, I.; Czupryniak, L.; Mankovsky, B. N.; Spallone, V.; Veresiu, I. A.; Schnell, O.; Ziegler, D.; Molnár, G. A.; Erbach, M.; Kempler, P.

In: Diabetes, Stoffwechsel und Herz, Vol. 24, No. 4, 01.08.2015, p. 251-255.

Research output: Contribution to journalArticle

Wittmann, I, Stirban, A, Tesfaye, S, Gurieva, I, Czupryniak, L, Mankovsky, BN, Spallone, V, Veresiu, IA, Schnell, O, Ziegler, D, Molnár, GA, Erbach, M & Kempler, P 2015, 'Neuropathy in chronic kidney disease', Diabetes, Stoffwechsel und Herz, vol. 24, no. 4, pp. 251-255.
Wittmann I, Stirban A, Tesfaye S, Gurieva I, Czupryniak L, Mankovsky BN et al. Neuropathy in chronic kidney disease. Diabetes, Stoffwechsel und Herz. 2015 Aug 1;24(4):251-255.
Wittmann, I. ; Stirban, A. ; Tesfaye, S. ; Gurieva, I. ; Czupryniak, L. ; Mankovsky, B. N. ; Spallone, V. ; Veresiu, I. A. ; Schnell, O. ; Ziegler, D. ; Molnár, G. A. ; Erbach, M. ; Kempler, P. / Neuropathy in chronic kidney disease. In: Diabetes, Stoffwechsel und Herz. 2015 ; Vol. 24, No. 4. pp. 251-255.
@article{054925fdcdda4f4e891f0ad768dccd72,
title = "Neuropathy in chronic kidney disease",
abstract = "Chronic kidney disease (CKD) has seen increasing prevalence, with current levels at around ten percent in adults aged twenty and over in industrialized western countries. CKD frequently affects both the central nervous system (CNS) and peripheral nervous system (PNS); uraemia, advanced glycation end-product (AGE) accumulation and oxidative stress, hyperkalemia, insulin resistance, adipocytokines, and erythropoietin deficiency and resistance have been identified as potential triggering factors. Typical neurological sequelae include uraemic encephalopathy, dialysis disequilibrium syndrome, and uraemic polyneuropathy. Impaired cerebral cognitive function has been demonstrated even in clinically asymptomatic stages in uraemic patients. In general, initiation of renal replacement treatment is indicated as the most promising therapeutic approach, possibly with symptomatic treatment of neuropathic pain with first-line drugs such as gabapentin, pregabalin, tricyclic antidepressants, and duloxetine. Additional treatment with benfotiamine may be considered as a pathogenesis-oriented measure in addressing the important role of inflammation and oxidative stress in the further renal function deterioration and nervous damage.",
keywords = "Chronic kidney disease, Diabetes, Neuropathy",
author = "I. Wittmann and A. Stirban and S. Tesfaye and I. Gurieva and L. Czupryniak and Mankovsky, {B. N.} and V. Spallone and Veresiu, {I. A.} and O. Schnell and D. Ziegler and Moln{\'a}r, {G. A.} and M. Erbach and P. Kempler",
year = "2015",
month = "8",
day = "1",
language = "English",
volume = "24",
pages = "251--255",
journal = "Diabetes und Stoffwechsel",
issn = "1861-7603",
publisher = "Verlag Kirchheim and Co. GmbH",
number = "4",

}

TY - JOUR

T1 - Neuropathy in chronic kidney disease

AU - Wittmann, I.

AU - Stirban, A.

AU - Tesfaye, S.

AU - Gurieva, I.

AU - Czupryniak, L.

AU - Mankovsky, B. N.

AU - Spallone, V.

AU - Veresiu, I. A.

AU - Schnell, O.

AU - Ziegler, D.

AU - Molnár, G. A.

AU - Erbach, M.

AU - Kempler, P.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Chronic kidney disease (CKD) has seen increasing prevalence, with current levels at around ten percent in adults aged twenty and over in industrialized western countries. CKD frequently affects both the central nervous system (CNS) and peripheral nervous system (PNS); uraemia, advanced glycation end-product (AGE) accumulation and oxidative stress, hyperkalemia, insulin resistance, adipocytokines, and erythropoietin deficiency and resistance have been identified as potential triggering factors. Typical neurological sequelae include uraemic encephalopathy, dialysis disequilibrium syndrome, and uraemic polyneuropathy. Impaired cerebral cognitive function has been demonstrated even in clinically asymptomatic stages in uraemic patients. In general, initiation of renal replacement treatment is indicated as the most promising therapeutic approach, possibly with symptomatic treatment of neuropathic pain with first-line drugs such as gabapentin, pregabalin, tricyclic antidepressants, and duloxetine. Additional treatment with benfotiamine may be considered as a pathogenesis-oriented measure in addressing the important role of inflammation and oxidative stress in the further renal function deterioration and nervous damage.

AB - Chronic kidney disease (CKD) has seen increasing prevalence, with current levels at around ten percent in adults aged twenty and over in industrialized western countries. CKD frequently affects both the central nervous system (CNS) and peripheral nervous system (PNS); uraemia, advanced glycation end-product (AGE) accumulation and oxidative stress, hyperkalemia, insulin resistance, adipocytokines, and erythropoietin deficiency and resistance have been identified as potential triggering factors. Typical neurological sequelae include uraemic encephalopathy, dialysis disequilibrium syndrome, and uraemic polyneuropathy. Impaired cerebral cognitive function has been demonstrated even in clinically asymptomatic stages in uraemic patients. In general, initiation of renal replacement treatment is indicated as the most promising therapeutic approach, possibly with symptomatic treatment of neuropathic pain with first-line drugs such as gabapentin, pregabalin, tricyclic antidepressants, and duloxetine. Additional treatment with benfotiamine may be considered as a pathogenesis-oriented measure in addressing the important role of inflammation and oxidative stress in the further renal function deterioration and nervous damage.

KW - Chronic kidney disease

KW - Diabetes

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84941915783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941915783&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84941915783

VL - 24

SP - 251

EP - 255

JO - Diabetes und Stoffwechsel

JF - Diabetes und Stoffwechsel

SN - 1861-7603

IS - 4

ER -